|
|
|
| 高危前列腺癌的术前新辅助内分泌治疗进展 |
| 顾良友, 张旭* |
| 中国人民解放军总医院第三医学中心泌尿外科医学部,北京 100853 |
|
[1] CHEN W, ZHENG R, BAADE P D, et al.Cancer statistics in China,2015[J]. CA Cancer J Clin,2016,66(2):115-132.
[2] MOTTET N, VAN DEN BERGH R, BRIERS E, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. part 1: screening, diagnosis, and local treatment with curative intent[J]. Eur Urol,2021,79(2):243-262.
[3] BANDINI M, FOSSATI N, GANDAGLIA G, et al.Neoadjuvant and adjuvant treatment in high-risk prostate cancer[J]. Expert Rev Clin Pharmacol,2018,11(4):425-438.
[4] KUMAR S, SHELLEY M, HARRISON C, et al. Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer[J]. Cochrane Database Syst Rev,2006 (4):CD006019.
[5] PIGNOT G, MAILLET D, GROSS E, et al.Systemic treatments for high-risk localized prostate cancer[J]. Nat Rev Urol,2018,15(8):498-510.
[6] PORCARO A B, TAFURI A, SEBBEN M, et al.High body mass index predicts multiple prostate cancer lymph node metastases after radical prostatectomy and extended pelvic lymph node dissection[J]. Asian J Androl,2020,22(3):323-329.
[7] ISAACS J T, COFFEY D S.Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma[J]. Cancer Res,1981,41(12 Pt 1):5070-5075.
[8] ANTONELLI A, PALUMBO C, VECCIA A, et al.Biological effect of neoadjuvant androgen-deprivation therapy assessed on specimens from radical prostatectomy: a systematic review[J]. Minerva Urol Nefrol,2018,70(4):370-379.
[9] PORCARO A B, DE LUYK N, CORSI P, et al.Clinical factors predicting bilateral lymph node invasion in High-Risk prostate cancer[J]. Urol Int,2017,99(4):392-399.
[10] SCHULMAN C C, SASSINE A M.Neoadjuvant hormonal deprivation before radical prostatectomy[J]. Clin Invest Med,1993,16(6):523-531.
[11] SOLOMON M H, MCHUGH T, DORR R P, et al.Hormone ablation therapy as neoadjuvant treatment to radical prostatectomy[J]. Clin Invest Med,1993,16(6):532-538.
[12] LIU W, YAO Y, LIU X, et al.Neoadjuvant hormone therapy for patients with high-risk prostate cancer: a systematic review and meta-analysis[J]. Asian J Androl,2021,23(4):429-436.
[13] MELLADO B, FONT A, ALCARAZ A, et al.Phase II trial of short-term neoadjuvant docetaxel and complete androgen blockade in high-risk prostate cancer[J]. Br J Cancer,2009,101(8):1248-1252.
[14] EASTHAM J A, HELLER G, HALABI S, et al.Cancer and leukemia group B 90203 (alliance):radical prostatectomy with or without neoadjuvant chemohormonal therapy in localized, High-Risk prostate cancer[J]. J Clin Oncol,2020,38(26):3042-3050.
[15] JOSHUA S, KEVIN C, HIREN P, et al.Interim analysis of phase 2 ramdomized prospective study on neoadjuvant apalutamide/abiraterone acetate with prednisone and the feasibility of performing nerve-sparing radical prostatectomy in men with high-risk prostate cancer[J]. J Urol,2020,203(4):e249-e249.
[16] MCKAY R R, YE H, XIE W, et al.Evaluation of intense androgen deprivation before prostatectomy: a randomized phase II trial of enzalutamide and leuprolide with or without abiraterone[J]. J Clin Oncol,2019,37(11):923-931.
[17] LEE L S, SIM A, ONG C W, et al. NEAR trial： A single-arm phase II trial of neoadjuvant apalutamide monotherapy and radical prostatectomy in intermediate- and high-risk prostate cancer[J]. Nature,2022,Published: 28 January 2022.https://doi.org/10.1038/s41391-022-00522-9.
[18] MARY-ELLEN T, MARTIN G, CHRISTOPHER PE, et al. PROTEUS: A randomized, double-blind, placebo-controlled, phase 3 trial of apalutamide plus androgen deprivation therapy versus PBO plus ADT prior to radical prostatectomy in patients with localized high-risk or locally advanced prostate cancer[J]. J Clin Oncol,2019,37(15 suppl):TPS5100-TPS5100.
[19] MONTGOMERY B, TRETIAKOVA M S, JOSHUA A M, et al.Neoadjuvant enzalutamide prior to prostatectomy[J]. Clin Cancer Res,2017,23(9):2169-2176.
[20] ANTHONY MJ, NEIL EF, JOSEPH C, et al. Abiraterone +/- cabazitaxel in defining complete response in prostatectomy (ACDC-RP) trial[J]. J Clin Oncol,2017,35(15 suppl):TPS5095. |
|
|
|
